Ajay Kshatriya, Aizen Therapeutics CEO (Photographer: F. Carter Smith/Bloomberg via Getty Images)
November 21, 2024 06:26 AM EST
R&D

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

Ayisha Sharma

News Reporter

Aizen Ther­a­peu­tics has left stealth with $13 mil­lion in seed fund­ing and a mis­sion to ad­vance “mir­ror pep­tide” drug can­di­dates, with an ini­tial fo­cus on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times